ANDA 211598, held by Hetero Labs. Voriconazole.
As of Nov 21, 2026, ANDA 211598 (Voriconazole), held by Hetero Labs, was first approved by FDA on Aug 8, 2025, with 1 approved supplement and 0 published complete response letters.
Voriconazole for oral suspension is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 8, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Voriconazole200MG/5ML · for suspension;oral | Voriconazole | Rx |
| Oct 19, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 8, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters